AbbVie: The Only Big Pharma Stock I'd Consider a Buy-and-Never-Sell [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
There were times when investors may have worried about hanging onto AbbVie (NYSE: ABBV) stock. A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the top-selling drug in the world at the time. But despite the 130 patents it received for Humira's various applications, sales were eventually going to drop once its patent protection expired and it faced generic competition. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Due to that competition, Humira's sales fell from $21.2 billion in 2023 to just $4.5 billion in 2025. But AbbVie's overall revenue was better than ever in 2025, thanks to the ascendance of two other immunology blockbusters: Skyrizi and Rinvoq. The company's ability to hold off generic competitors long
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- ???????????????????? : ????????:2035????1856?9000??????????CAGR17.9%???????????????????? [CNET News]CNET News
- ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTSPR Newswire
- OSE narrows pipeline focus amid Boehringer MASH collaboration retreat [Yahoo! Finance]Yahoo! Finance
- AbbVie to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- AbbVie to Present at the Leerink Partners Global Healthcare ConferencePR Newswire
ABBV
Earnings
- 2/4/26 - Miss
ABBV
Sec Filings
- 3/4/26 - Form 8-K
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- ABBV's page on the SEC website